LABD Performance — Direxion Daily S&P Biotech Bear 3X Shares
Data updated: 2026-09-28
LABD returned −55.16% year to date and −85.59% over one year to Jul 2026. Annualised returns are −57.78% over 3 years and −46.66% over 5 years. The fund trailed its Trading - Inverse category average: $100 invested three years ago grew to $8, against $39 for the category, and to $14 over one year, against $73. Volatility over the past three years was 73.76% a year. In the 12 months to Jul 2026 the fund took in a net $121.7M, and assets reached $54.20M.
LABD Growth of $100
What $100 invested in Direxion Daily S&P Biotech Bear 3X Shares grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Trading - Inverse category average over the same months.
| Period | LABD | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $14 | $73 |
| 3 years (Aug 2023 – Jul 2026) | $8 | $39 |
| 5 years (Aug 2021 – Jul 2026) | $4 | $35 |
| Since data start (Aug 2019 – Jul 2026) | $0 | $12 |
LABD Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | −55.16% |
| 1 year | −85.59% |
| 3 years (annualised) | −57.78% |
| 5 years (annualised) | −46.66% |
LABD Annual Returns
Calendar-year total returns of Direxion Daily S&P Biotech Bear 3X Shares, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | −55.16% |
| 2025 | −70.18% |
| 2024 | −21.59% |
| 2023 | −41.61% |
| 2022 | −32.91% |
| 2021 | +2.14% |
| 2020 | −89.75% |
| 2019 (Aug–Dec) | −34.99% |
LABD Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −8.8% | −8.0% | −7.5% | −9.3% | −13.7% | −39.1% | +21.0% | — | — | — | — | — |
| 2025 | −9.1% | +13.1% | +27.7% | −16.8% | +10.1% | −13.4% | −10.9% | −13.6% | −29.3% | −30.8% | −24.2% | +0.4% |
| 2024 | +3.6% | −33.3% | +9.3% | +39.0% | −15.6% | −13.0% | −18.7% | −7.9% | +7.3% | +6.0% | −9.9% | +32.6% |
| 2023 | −20.2% | +21.2% | +24.7% | −17.9% | −16.7% | +2.7% | −4.0% | +19.8% | +26.3% | +29.8% | −36.6% | −42.3% |
| 2022 | +50.3% | +2.9% | −12.0% | +63.5% | −1.1% | −31.5% | −29.9% | −18.1% | +7.5% | −15.8% | −12.1% | −2.5% |
| 2021 | −24.7% | +2.8% | +11.5% | −6.7% | +16.2% | −18.3% | +27.2% | −24.0% | +14.5% | 0.0% | +19.3% | +1.3% |
| 2020 | +19.8% | −4.4% | −0.9% | −50.7% | −32.2% | −25.7% | +3.2% | −11.0% | −6.7% | −8.3% | −42.5% | −19.4% |
| 2019 | — | — | — | — | — | — | — | +16.6% | +14.5% | −19.6% | −35.4% | −6.3% |
LABD Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 73.76%
- 3-year Sharpe ratio: -0.84 (vs 4.5% risk-free rate)
- Best month: +38.98% (Apr 2024)
- Worst month: −42.35% (Dec 2023)
LABD Fund Flows
Monthly money in and out of Direxion Daily S&P Biotech Bear 3X Shares, from SEC Form N-PORT.
- 12-month net flow: $121.7M
- 12-month gross sales (incl. reinvestments): $763.1M
- Sales ÷ redemptions: 1.19×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $53.2M | $80.7M | −$27.5M |
| Jun 2026 | $98.1M | $72.8M | $25.3M |
| May 2026 | $79.2M | $61.2M | $18.1M |
| Apr 2026 | $97.3M | $108.5M | −$11.2M |
| Mar 2026 | $85.8M | $59.1M | $26.6M |
| Feb 2026 | $31.7M | $32.6M | −$934K |
| Jan 2026 | $41.7M | $41.0M | $775K |
| Dec 2025 | $32.9M | $40.8M | −$7.8M |
| Nov 2025 | $73.2M | $41.7M | $31.5M |
| Oct 2025 | $55.6M | $24.6M | $30.9M |
| Sep 2025 | $64.3M | $38.4M | $25.9M |
| Aug 2025 | $50.1M | $39.9M | $10.2M |
LABD Assets Under Management
Net assets of Direxion Daily S&P Biotech Bear 3X Shares by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $54.20M |
| 2026-04-30 | $68.09M |
| 2026-01-31 | $73.16M |
| 2025-10-31 | $73.00M |
| 2025-07-31 | $63.12M |
| 2025-04-30 | $44.85M |
| 2025-01-31 | $55.35M |
| 2024-10-31 | $85.54M |
| 2024-07-31 | $155.14M |
| 2024-04-30 | $99.03M |
| 2024-01-31 | $139.89M |
| 2023-10-31 | $61.93M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.